Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow‐up

Abstract Background This study described the clinical features of patients with pterygium and analyzed the recurrence rate of conjunctival autografting alone, conjunctival autografting combined with intraoperative mitomycin C, and amniotic membrane grafting. Methods A retrospective cohort study of primary pterygium was conducted between January 2017 and February 2020. Factors associated with pterygium severity and recurrence were analyzed by univariate analysis and logistic regression models. Results The study included 292 patients with an average age of 53.3 ± 14.1 years, while the number of operated cases was 94. Pterygia involving the cornea were observed in 55 % of the cases. The overall rate of recurrence for the three procedures was 17 %. The average time of recurrence was 14.2 ± 11.9 months, with 37 % of the recurrences occurring after the first year. The only factor associated with a significant risk of recurrence was dry eye disease in both univariate (p = 0.021) and multivariate analysis (p = 0.026). The recurrence rates following conjunctival autografting with and without mitomycin C were 15.6 and 15.8 %, respectively. The recurrence rate following the amniotic membrane graft was twofold (OR= 2.02) (27 %) that following the conjunctival autograft (15.8 %). Conclusions The only factor associated with the recurrence of pterygium was dry eye disease. More than one-third of recurrences developed after the first year, which stresses the importance of a long follow-up. The recurrence rate in our study following conjunctival graft was slightly higher compared to the literature mainly due to differences in study areas, populations, and follow-up periods.

Download Full-text

Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2015-306930 ◽

2016 ◽

Vol 100 (11) ◽

pp. 1547-1550 ◽

Cited By ~ 5

Author(s):

Morgane Straub ◽

Alain M Bron ◽

Aurore Muselier-Mathieu ◽

Catherine Creuzot-Garcher

Keyword(s):

Dry Eye ◽

Dry Eye Disease ◽

Eye Disease ◽

Term Outcome ◽

Long Term Outcome

Download Full-text

Dry Eye Disease following Refractive Surgery: A 12-Month Follow-Up of SMILE versus FS-LASIK in High Myopia

Journal of Ophthalmology ◽

10.1155/2015/132417 ◽

2015 ◽

Vol 2015 ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

Bingjie Wang ◽

Rajeev K. Naidu ◽

Renyuan Chu ◽

Jinhui Dai ◽

Xiaomei Qu ◽

...

Keyword(s):

Observational Study ◽

Dry Eye ◽

High Myopia ◽

Refractive Surgery ◽

Dry Eye Disease ◽

Eye Disease ◽

Evaluation Questionnaire

Purpose.To compare dry eye disease following SMILE versus FS-LASIK.Design.Prospective, nonrandomised, observational study.Patients.90 patients undergoing refractive surgery for myopia were included. 47 eyes underwent SMILE and 43 eyes underwent FS-LASIK.Methods.Evaluation of dry eye disease was conducted preoperatively and at 1, 3, 6, and 12 months postoperatively, using the Salisbury Eye Evaluation Questionnaire (SEEQ) and TBUT.Results.TBUT reduced following SMILE at 1 and 3 months (p<0.001) and at 1, 3, and 6 months following FS-LASIK (p<0.001). TBUT was greater following SMILE than FS-LASIK at 3, 6, and 12 months (p<0.001,p<0.001, andp=0.009, resp.). SEEQ scores increased (greater symptoms) following SMILE at 1 month (p<0.001) and 3 months (p=0.003) and at 1, 3, and 6 months following FS-LASIK (p<0.001). SMILE produced lower SEEQ scores (fewer symptoms) than FS-LASIK at 1, 3, and 6 months (p<0.001).Conclusion.SMILE produces less dry eye disease than FS-LASIK at 6 months postoperatively but demonstrates similar degrees of dry eye disease at 12 months.

Download Full-text

Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease

Journal of Ophthalmology ◽

10.1155/2017/6404918 ◽

2017 ◽

Vol 2017 ◽

pp. 1-10 ◽

Cited By ~ 9

Author(s):

Thomas John ◽

Sean Tighe ◽

Hosam Sheha ◽

Pedram Hamrah ◽

Zeina M. Salem ◽

...

Keyword(s):

Nerve Regeneration ◽

Dry Eye ◽

Amniotic Membrane ◽

Signs And Symptoms ◽

Dry Eye Disease ◽

Eye Disease ◽

Study Group ◽

Corneal Sensitivity ◽

Corneal Nerve

Purpose. To evaluate the efficacy of self-retained cryopreserved amniotic membrane (CAM) in promoting corneal nerve regeneration and improving corneal sensitivity in dry eye disease (DED).Methods. In this prospective randomized clinical trial, subjects with DED were randomized to receive CAM (study group) or conventional maximum treatment (control). Changes in signs and symptoms, corneal sensitivity, topography, and in vivo confocal microscopy (IVCM) were evaluated at baseline, 1 month, and 3 months.Results. Twenty subjects (age 66.9 ± 8.9) were enrolled and 17 completed all follow-up visits. Signs and symptoms were significantly improved in the study group yet remained constant in the control. IVCM showed a significant increase in corneal nerve density in the study group (12,241 ± 5083 μm/mm2at baseline, 16,364 ± 3734 μm/mm2at 1 month, and 18,827 ± 5453 μm/mm2at 3 months,p=0.015) but was unchanged in the control. This improvement was accompanied with a significant increase in corneal sensitivity (3.25 ± 0.6 cm at baseline, 5.2 ± 0.5 cm at 1 month, and 5.6 ± 0.4 cm at 3 months,p<0.001) and corneal topography only in the study group.Conclusions. Self-retained CAM is a promising therapy for corneal nerve regeneration and accelerated recovery of the ocular surface health in patients with DED. The study is registered at clinicaltrials.gov with trial identifier:NCT02764814.

Download Full-text

Recurrence rate and clinical outcome of amniotic membrane transplantation combined with mitomycin c in pterygium surgery: Two-year follow-up

Journal of Research in Pharmacy Practice ◽

10.4103/jrpp.jrpp_19_127 ◽

2020 ◽

Vol 9 (1) ◽

pp. 10

Author(s):

Seyed-Abolfazl Kashfi ◽

Hasan Razmjoo ◽

Majid Mirmohammadkhani ◽

Mohsen Pourazizi

Keyword(s):

Clinical Outcome ◽

Mitomycin C ◽

Recurrence Rate ◽

Amniotic Membrane ◽

Amniotic Membrane Transplantation ◽

Pterygium Surgery

Download Full-text

Clinical Trial to Evaluate the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET Study)

Case Medical Research ◽

10.31525/ct1-nct03920215 ◽

2019 ◽

Author(s):

Keyword(s):

Clinical Trial ◽

Nasal Spray ◽

Dry Eye ◽

Signs And Symptoms ◽

Dry Eye Disease ◽

Eye Disease ◽

Long Term Follow Up

Download Full-text

Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane

The Ocular Surface ◽

10.1016/j.jtos.2015.07.003 ◽

2016 ◽

Vol 14 (1) ◽

pp. 56-63 ◽

Cited By ~ 13

Author(s):

Anny M.S. Cheng ◽

Dandan Zhao ◽

Rendian Chen ◽

Han Y. Yin ◽

Sean Tighe ◽

...

Keyword(s):

Dry Eye ◽

Amniotic Membrane ◽

Ocular Surface ◽

Dry Eye Disease ◽

Eye Disease ◽

Ocular Surface Health

Download Full-text

Amniotic membrane in dry-eye disease: better outcomes at lower cost

PharmacoEconomics & Outcomes News ◽

10.1007/s40274-020-7335-y ◽

2020 ◽

Vol 868 (1) ◽

pp. 3-3

Keyword(s):

Dry Eye ◽

Amniotic Membrane ◽

Lower Cost ◽

Dry Eye Disease ◽

Eye Disease

Download Full-text

Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-020-00252-6 ◽

2020 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Jeffrey Voigt

Keyword(s):

Dry Eye ◽

Amniotic Membrane ◽

Cyclosporine A ◽

Cost Utility ◽

Dry Eye Disease ◽

Eye Disease ◽

Base Case ◽

Societal Costs ◽

One Year ◽

Topical Medications

Abstract Background The purpose is to perform a cost effectiveness analysis amniotic membrane vs. topical medications in the use of treating dry eye disease. A cost effectiveness analysis comparing amniotic membrane + other topical medications to topical cyclosporine A + other topical medications was evaluated using accepted decision tree modeling software. Methods TreeAge Pro 2019 software was used to evaluate the base case costs over a one year timeframe. Sensitivity analysis was performed on those variables which had the greatest effect on choosing one therapy versus the other based on cost. Monte Carlo simulation was run 1,000 times to determine the most effective, least costly alternative. Costs were evaluated from a societal level (direct + indirect). Quality of life utility scores were evaluated using known time tradeoffs from prior studies (scale 0–1; with 1 being perfect vision). Results Over a one year timeframe, the base case demonstrated that amniotic membrane + topical medications was the less expensive alternative and provided for incremental utilities versus topical cyclosporine + other medications (Cost/utility: $18,275/0.78 vs. $20,740/0.74). If examining direct costs only, topical cyclosporine was the least expensive option over a one year timeframe: $4,112 vs. $10,300. Sensitivity analysis demonstrated that in order for topical cyclosporine to be the less expensive alternative the following variables would need to be: < 68 days productivity lost; < $161 productivity lost/day; > 79% of amniotic membrane implants would need to be re-implanted at month 4 (for whatever reason); > $2677 per amniotic membrane implant procedure (Medicare reimbursement rate); > 96% positive response to topical cyclosporine A at month 4; > 58% positive response to topical cyclosporine A at month 6 and; < 54% probability clinical improvement with amniotic membrane. Monte Carlo simulation demonstrated that amniotic membrane was the less costly, most effective alternative 91.5% of the time. Conclusion Based on improved outcomes using amniotic membrane, patient productivity was improved resulting in lower societal costs (less days lost from work). When considering the untoward effects of dry eye disease on societal costs, an improvement of the dry eye disease condition was accomplished most often with amniotic membrane.

Download Full-text

Treatment Trends in Dry Eye Disease and Factors Associated with Ophthalmic Follow-up Discontinuation in Japan

Journal of Clinical Medicine ◽

10.3390/jcm8081120 ◽

2019 ◽

Vol 8 (8) ◽

pp. 1120 ◽

Cited By ~ 1

Author(s):

Miki Uchino ◽

Norihiko Yokoi ◽

Motoko Kawashima ◽

Yamanishi Ryutaro ◽

Yuichi Uchino ◽

...

Keyword(s):

Risk Factors ◽

Risk Factor ◽

Dry Eye ◽

Past History ◽

Significant Risk ◽

Significant Risk Factor ◽

Dry Eye Disease ◽

Eye Disease ◽

History Of

Despite the importance of dry eye disease (DED) treatment, the rate of DED treatment discontinuation, especially discontinuation of ophthalmic follow-up, remains unknown. This study aimed to assess the prevalence and risk factors of ophthalmic follow-up discontinuation for DED. A cross-sectional survey of 1030 participants was conducted using a self-administered web-survey instrument. We collected lifestyle information, history of DED diagnosis, types of treatment, frequency of eye-drop usage, symptoms, and the reasons for discontinuing treatment. Statistical analyses including logistic regression were used to evaluate the risk factors of discontinuing ophthalmic follow-up for DED. A past history of clinical DED diagnosis was reported by 155 (15.0%) subjects. Of those, 130 had persistent DED, and 88 (67.7%) of the subjects reported discontinuation of ophthalmic follow-up for DED. The most prevalent reasons for ophthalmic follow-up discontinuation were time restrictions, followed by dissatisfaction with the DED treatment. Duration after DED diagnosis was the only significant risk factor for discontinuing ophthalmic follow-up after adjusting for age and sex (odds ratio = 1.09, 95% confidence interval = 1.02–1.17, p = 0.009). In conclusion, longer DED duration after diagnosis was a significant risk factor for discontinuing ophthalmic follow-up for DED. This study showed that DED ophthalmic follow-up discontinuation involves both medical and non-medical reasons. Clinicians need to be aware of them, and preventative effort is needed to avoid discontinuation.

Download Full-text